Ventrus Biosciences, a specialty pharmaceutical company based in Greenwood Village, focused on the late-stage development and commercialization of gastrointestinal products, and Sam Amer & Co. (who I need to dig up some additional info on – a simple google search yields nada…) announced an agreement granting Ventrus exclusive world wide rights to develop and commercialize Iferanserin (VEN309) a Phase III topical ointment for the treatment of hemorrhoids. Under the terms of the agreement Ventrus has been granted exclusive world-wide development and marketing rights in exchange of up-front payments on the execution of the license followed by potential milestone and royalty payments if VEN309 is successfully developed and commercialized. Iferanserin ointment has an active IND submission file at the FDA. Based on a February 2008 meeting with the FDA, Ventrus is preparing a special protocol assessment request, and plans to initiate the first Phase III trials for iferanserin ointment early in 4Q08.
Ventrus concentrates on licensing late-stage gastrointestinal products in areas of unmet need. The development strategy for each asset is based on the most efficient path to regulatory approval, with the full potential of each asset achieved by means of additional post-marketing indications.
For more info on the Ventrus model be certain to take a look at the beautiful new website that President & CEO Thom Rowland recently launched...take a look (here).
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).